Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD2 | P25440 | 17/20 | 0.63 |
| ▸ | BRD4 | O60885 | 14/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20288795 | 0.90 | BRD4 (0.66) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20288764 | 0.88 | BRD2 (0.69) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20288798 | 0.88 | BRD2 (0.66) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20288804 | 0.87 | BRD4 (0.63) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL26487137 | 0.87 | BRD2 (0.65) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20289274 | 0.87 | BRD2 (0.67) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20270151 | 0.87 | BRD4 (0.69) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20270666 | 0.87 | BRD4 (0.69) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL20288524 | 0.85 | BRD2 (0.69) | BRD2BRD4BRD3HDAC1HDAC7 | |
| SCHEMBL30609240 | 0.85 | BRD2 (0.69) | BRD2BRD4BRD3HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST JUDE CHILDRENS RES HOSPITAL (US) | 2021-06-24 | — | — | US | disclosed |
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2018111805-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-20210188777-A1 | TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
| US-11787768-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | BRD2 4/4885BRD4 2/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.